# Multiple Myeloma Definition-Of-Complete Audit v0

Stewarded by [frg.earth](https://frg.earth/).

- disease program: `multiple-myeloma`
- artifact id: `multiple-myeloma-definition-of-complete-audit-v0`
- claim level: open-question
- clinical boundary: research-use-only, not medical advice
- audit boundary: public-loop completion audit, not scientific completion
- last reviewed: `2026-04-15`

## Purpose

This audit checks the public multiple myeloma loop against the definition of
complete in [Clawdad Autonomous Research Loop v0](../../protocols/clawdad-autonomous-research-loop-v0.md)
before selecting any new public task.

It exists to prevent the project from extending the review-packet-builder lane
or schema ladder by momentum. It asks whether the next action is a concrete
public-safe gap, an explicit blocker, a private-lab handoff, or completion of
the current public loop.

## Phase Handoff Guard

| Check | Finding | Audit Decision |
| --- | --- | --- |
| Ready task queue before audit | `make list-public-tasks ARGS="--status ready"` reported zero ready tasks. | Do not invent a task from queue momentum. |
| Validation state before audit | `make validate` passed. | Treat the repo as validation-green before the audit edit. |
| Named endpoint | The review-builder recombination handoff names a definition-of-complete audit as the next aggregate work object. | This audit is the current finite endpoint. |
| Review-builder lane | Manifest, dry run, route table, output schema, packet-assembly gate, skeleton spec, and recombination handoff are present. | Keep packet assembly, generated packets, generated biomedical prose, ranking, patient matching, trial matching, recommendations, and publication workflow blocked. |
| Generalization opportunity | The remaining question spans roadmap, case-to-cure, fixtures, source registry, validators, navigation, and private-lab blockers. | Use an audit matrix instead of adding another builder/schema sibling. |

## Inputs Audited

| Input | Audit Use |
| --- | --- |
| [Multiple Myeloma Public Roadmap v0](public-roadmap-v0.md) | Roadmap tasks, phase boundary, and immediate queue. |
| [Case-To-Cure Pipeline Blueprint v0](case-to-cure-pipeline-blueprint-v0.md) | Case stages, private/public zones, gates, and remaining private-only commands. |
| [Multiple Myeloma Synthetic Case-To-Cure Pipeline v0](../../examples/multiple-myeloma-synthetic-case-to-cure-pipeline-v0.md) | Synthetic fixture coverage for `case_00` through `case_14`. |
| [Public Artifact Catalog v0](../../artifacts/public-artifact-catalog-v0.md) | Public artifact navigation and metadata-backed listing. |
| [Source Registry v0](../../sources/source-registry-v0.md) | Reusable public source anchors for the first open research map. |
| [Schema And Tooling Phase Inventory v0](schema-tooling-phase-inventory-v0.md) | Schema/tooling endpoint and blocked implementation lanes. |
| [Review-Packet Builder Recombination Handoff v0](reviews/review-packet-builder-recombination-handoff-v0.md) | Review-builder lane endpoint and audit handoff. |
| [Private To Public Workflow](../../docs/private-to-public-workflow.md) | Public release requirements and private upstream boundary. |
| [Public Safety](../../governance/PUBLIC_SAFETY.md) | Repository-wide safety constraints. |

## Definition-Of-Complete Matrix

| Criterion | Audit Status | Public Evidence | Remaining Gap Or Decision |
| --- | --- | --- | --- |
| Every roadmap item has a public artifact, public task, schema, protocol, validator, or explicit blocked status. | Complete for current v0 roadmap queue. | The roadmap task queue has no ready tasks before this audit, and completed tasks point to public artifacts, schemas, gates, or handoffs. | Future tooling lanes remain blocked by gates and should not restart without a new aggregate checkpoint. |
| The case-to-cure blueprint has public-safe schema summaries, gate checklists, and synthetic fixtures for each stage. | Mostly complete, with one blocker-register gap. | The blueprint names `case_00` through `case_14`; the synthetic example covers all stages; the case-feature summary, candidate-option rubric, publication gate, review template, and route-table artifacts define public-safe boundaries. | A consolidated public register should map remaining real-case steps to private-lab tasks or human-gated blockers. |
| The first multiple myeloma open research map is present and source-backed. | Complete for v0.1. | The open research map and JSON companion exist and validate against Disease Map Schema v0. | Future map expansion is source-backed research work, not a completion blocker for v0. |
| Source registry entries are sufficient for the first open research map. | Complete for v0.1. | The source registry has target, therapy, trial, regulatory, labeling, dataset, PubMed, ClinicalTrials.gov, FDA, NCI, and measurement-source anchors used by current artifacts. | Source presence does not prove efficacy, safety, eligibility, current availability, or patient fit. |
| Validators pass across metadata, catalogs, source links, task references, and schema examples. | Complete before this audit edit. | `make validate` passed and the route-table output, manifest, disease-map, target, therapy, trial-landscape, open-question, and synthetic-pipeline examples validate. | Re-run validation after this audit and task-queue edit. |
| Public README and catalog paths make the work navigable. | Complete after this audit is wired. | The disease-program README and public artifact catalog link the current active artifacts and review-builder handoff. | Add this audit to catalog and README navigation. |
| All remaining case-specific steps are represented as private-lab tasks or human-gated blockers. | Incomplete. | The blueprint names private-only paths, case gates, future private commands, clinical owner signoff, trial-site or sponsor verification, safety review, and publication review. | Create a public-safe case-specific private-lab blocker register that consolidates those blockers without real case data. |

Step 32 follow-up: [Case-Specific Private-Lab Blocker Register v0](case-specific-private-lab-blocker-register-v0.md)
now maps `case_00` through `case_14` to private-lab tasks or human-gated
blockers. It resolves the blocker-register gap for the current v0 public loop
without adding real case data, case-processing code, patient-specific review,
or clinical guidance.

Step 33 follow-up: [Public Loop Completion Handoff v0](public-loop-completion-handoff-v0.md)
marks the current v0 public loop endpoint after the blocker-register gap is
resolved. It selects no new ready public task.

## Selected Next Work

The single next public-safe task is:

`multiple-myeloma-case-specific-private-lab-blocker-register-task-v0`

Why this is the right next item:

- it is the only incomplete definition-of-complete criterion found by the
  audit
- it can be completed from existing public artifacts without private case data
- it makes case-specific work visibly private-lab or human-gated instead of
  implied by prose
- it does not require credentials, paid services, institutional decisions,
  clinician decisions, sponsor decisions, account changes, or real case access
- it blocks patient-specific diagnosis, prognosis, treatment advice, trial
  advice, expanded-access guidance, monitoring advice, and option ranking

## Not Selected

This audit does not select:

- review-packet assembly code
- generated review packets
- packet-output schemas that imply filled packet content
- evidence graph tooling
- trial explorer tooling
- target prioritization views
- extraction-helper code
- public explainer generation
- real case handling
- publication workflow

Those lanes remain blocked until a future aggregate gate names a bounded,
validated, public-safe endpoint.

## Public Safety Check

- No patient-identifying data.
- No real case data.
- No private records.
- No credentials, paid APIs, account changes, or restricted datasets.
- No patient-specific diagnosis, prognosis, treatment, trial, expanded-access,
  monitoring, or candidate-option guidance.
- No target, therapy, trial, source, mechanism, artifact, task, or evidence
  ranking.
- No generated biomedical claims.
- No expert-review substitution.
- No publication authorization.
- No cure claim.

## Limitations

- This audit does not prove the science is complete.
- This audit does not prove source coverage is comprehensive.
- This audit does not make any artifact expert-reviewed.
- This audit does not authorize review-packet assembly or generated outputs.
- This audit does not inspect private lab records.
- This audit does not verify any real case, real trial, sponsor pathway,
  clinician decision, regulatory decision, institutional decision, or
  publication decision.
- This audit does not provide medical advice, diagnostic guidance, treatment
  guidance, trial guidance, eligibility guidance, expanded-access guidance,
  monitoring guidance, or a cure claim.
